Here, the aberrant reduction of Nrf2 during the (myo)fibroblastic activation of fibroblast and the overexpression of Nrf2 in fibroblast that attenuated TGF-β1-mediated (myo)fibroblastic activation suggested that Nrf2 could be a valuable therapeutic target of PF. This evidence concerns the gene TGFB1 and pemphigus foliaceus.